25 completed, 7 terminated, 5 unknown, 2 withdrawn. 41 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 41 | Completed 25, Terminated 7, Unknown 5, Withdrawn 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 4 | Unknown 3, Completed 1 |
Follow Cancer Pain: new trials by email Literature Review of Cancer Pain trials Research Report on Cancer Pain
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Non-opioid Drugs in Addition to Opioid Therapy for Cancer Pain Management Metamizole, Ibuprofen, Placebo - Cancer Pain, Cancer Palliative Care | Phase 3 | Not yet recruiting | University Hospital, Basel, Switzerland | 318 | 2026-10-01 | 2026-08-19 |
| A Randomized Controlled Trial of a Web-based Platform for Cancer Pain Management a patient self-reporting applet - Cancer Pain | Phase 3 | Recruiting | West China Hospital | 100 | 2024-11-10 | 2026-04-30 |
| NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers NanaBis™, Oxycodone CR, Placebo Spray - Cancer Related Pain | Phase 3 | Unknown | Medlab Clinical | 360 | 2023-11-01 | 2022-04-12 |
| Methadone for 'Adenocarcinopathic' Pain Treatment Methadone, Morphine - Cancer Pain, Adenocarcinoma | Phase 3 | Withdrawn | Ottawa Hospital Research Institute | 2022-09-01 | 2022-12-05 | |
| Subcutaneous Versus Intravenous Morphine When Switching From Oral to Parenteral Route in Palliative Cancer Patients Morphine - Pain Cancer | Phase 3 | Completed | University Hospital, Akershus | 60 | 2022-03-08 | 2025-03-06 |
| PARASTOP - Paracetamol With Strong Opioids Paracetamol, Placebo - Cancer Pain, Cancer | Phase 3 | Completed | Oslo University Hospital | 204 | 2021-10-20 | 2026-02-25 |
| IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration Hydromorphone Hydrochloride Injection, Morphine Sulfate Sustained-release Tablets - Cancer Pain | Phase 3 | Completed | Fujian Cancer Hospital | 1372 | 2021-07-01 | 2025-05-22 |
| The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy Venlafaxine, Memantine - Oncology Pain, Chemotherapy-induced Peripheral Neuropathy | Phase 2 / Phase 3 | Unknown | Mendel AI | 60 | 2021-02-15 | 2021-02-04 |
| Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain Resiniferatoxin, Standard of Care - Pain, Intractable, Pain Cancer | Phase 3 | Withdrawn | Sorrento Therapeutics, Inc. | 2020-12-01 | 2021-11-09 | |
| Efficacy of Myofascial Pain Syndrome Treatment in Patients With Cancer in Palliative Care 1% lidocaine injection in trigger points - Myofascial Pain Syndromes, Cancer | Phase 3 | Completed | University of Sao Paulo | 30 | 2020-08-17 | 2023-04-25 |
| A Study to Evaluate Buprenorphine Transdermal Patch in Chinese Subjects With Moderate to Severe Chronic Cancer Pain Buprenorphine transdermal patches, Morphine Sulfate Sustained-Release Tablet - Cancer Pain | Phase 3 | Unknown | Mundipharma (China) Pharmaceutical Co. Ltd | 194 | 2019-04-22 | 2019-06-11 |
| PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain Hydromorphone, PCA pump - Cancer Pain | Phase 3 | Completed | Fujian Cancer Hospital | 214 | 2018-09-29 | 2021-03-08 |
| Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies Investigational medical product (IMP) administered in parent study - Osteoarthritis, Cancer Pain | Phase 3 | Completed | Pfizer | 4 | 2017-11-03 | 2021-06-25 |
| Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy Tanezumab - Bone Metastasis, Cancer Pain | Phase 3 | Completed | Pfizer | 156 | 2015-10-28 | 2023-02-16 |
| CORAL XT - Open-label Extension Trial of the CORAL Trial Cebranopadol - Pain, Neoplasms | Phase 3 | Completed | Tris Pharma, Inc. | 76 | 2013-12-18 | 2021-07-15 |
| CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer Cebranopadol, Morphine Prolonged Release - Pain, Neoplasms | Phase 3 | Terminated | Tris Pharma, Inc. | 200 | 2013-10-29 | 2021-07-15 |
| A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer Nabiximols, Placebo (GA-0034) - Pain, Advanced Cancer | Phase 3 | Completed | Jazz Pharmaceuticals | 406 | 2012-06-29 | 2023-04-12 |
| Real-time Cancer Pain Assessment and Intervention real-time monitoring and instruction of cancer pain, standard cancer pain care - Malignancy, Pain | Phase 2 / Phase 3 | Unknown | Sun Yat-sen University | 200 | 2012-03-01 | 2015-08-27 |
| Subcutaneous Lidocaine For Cancer-Related Pain Lidocaine, Placebo (D5W) - Cancer-related Pain | Phase 2 / Phase 3 | Completed | British Columbia Cancer Agency | 33 | 2011-12-01 | 2019-07-12 |
| Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain NKTR-118, Placebo - Opioid-Induced Constipation | Phase 3 | Terminated | AstraZeneca | 14 | 2011-06-01 | 2015-06-01 |
Showing 20 of 41. Sign in to see all of them.
Pain (18) · Neoplasms (15) · Chronic Pain (4) · Adenocarcinoma (1) · Breakthrough Pain (1) · Low Back Pain (1) · Lung Neoplasms (1) · Multiple Myeloma (1) · Myofascial Pain Syndromes (1) · Neuralgia (1) · Opioid-Induced Constipation (1) · Osteoarthritis (1) · Pain, Intractable (1)
Neurologic Manifestations (41) · Pathological Conditions, Signs and Symptoms (41) · Signs and Symptoms (41) · Pain (23) · Musculoskeletal Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Arthritis (1) · Back Pain (1) · Blood Protein Disorders (1) · Carcinoma (1) · Cardiovascular Diseases (1) · Chemically-Induced Disorders (1) · Constipation (1) · Hematologic Diseases (1)
Morphine (6) · nabiximols (4) · Acetaminophen (3) · Fentanyl (3) · Methadone (3) · Oxycodone (3) · 6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine (2) · Hydromorphone (2) · Lidocaine (2) · Dipyrone (1) · Donepezil (1) · Glucose (1) · Ibuprofen (1) · Inosine Monophosphate (1) · Memantine (1)
Jazz Pharmaceuticals (3) · Kyowa Kirin Co., Ltd. (3) · Alza Corporation, DE, USA (2) · Fujian Cancer Hospital (2) · M.D. Anderson Cancer Center (2) · Mundipharma (China) Pharmaceutical Co. Ltd (2) · Pfizer (2) · Tris Pharma, Inc. (2) · Archimedes Development Ltd (1) · AstraZeneca (1) · British Columbia Cancer Agency (1) · Chonnam National University Hospital (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Faculdade de Medicina do ABC (1) · GW Pharmaceuticals Ltd (1)
Poland (9) · Romania (9) · United Kingdom (9) · United States (9) · Bulgaria (8) · Germany (8) · Hungary (8) · China (6) · Czechia (6) · Spain (6) · Australia (5) · Belgium (5) · Japan (5) · Slovakia (5) · Austria (4)
Eduardo Bruera, MD (2) · Auro del Giglio (1) · Bruno Gagnon, MD MSc (1) · Christopher Boehlke, Prof. Dr. (1) · Daniel IG Cubero (1) · David Warr, MD (1) · Hans Georg Kress, Dr. (1) · Ian Tannock, MD, PhD (1) · Janette Vardy, MD (1)
PMID 10506634, PMID 11387363, PMID 14701781, PMID 15310785, PMID 16051965, PMID 20822038, PMID 24839047, PMID 24906437, PMID 25054392, PMID 25378647, PMID 27062079, PMID 30365202, PMID 31152783, PMID 37343145, PMID 38484328, PMID 9779694, PMID 9817288
2009 (3), R01CA124481 (1)